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Dietary protein as casein (CAS) augments intrinsic acid
production, induces endothelin-mediated kidney
acidification, and promotes kidney injury. We tested the
hypothesis that dietary CAS induces endothelin-mediated
kidney injury through augmented intrinsic acid production.
Munich–Wistar rats ate minimum electrolyte diets from age
8 to 96 weeks with 50 or 20% protein as either acid-inducing
CAS or non-acid-inducing SOY. Urine net acid excretion and
distal nephron net HCO3 reabsorption by in vivo
microperfusion (Net JHCO3) were higher in 50 than 20% CAS
but not 50 and 20% SOY. At 96 weeks, 50% compared the
20% CAS had higher urine endothelin-1 excretion (UET-1V)
and a higher index of tubulo-interstitial injury (TII) at
pathology (2.2570.21 vs 1.2570.13 U, Po0.03), but each
parameter was similar in 50 and 20% SOY. CAS (50%) eating
NaHCO3 to reduce intrinsic acid production had lower Net
JHCO3, lower UET-1V, and less TII. By contrast, 50% SOY eating
dietary acid as (NH4)2SO4 had higher Net JHCO3, higher UET-1V,
and more TII. Endothelin A/B but not A receptor antagonism
reduced Net JHCO3 in 50% CAS and 50% SOYþ (NH4)2SO4
animals. By contrast, endothelin A but not A/B receptor
antagonism reduced TII in each group. The data support that
increased intake of acid-inducing dietary protein induces
endothelin B-receptor-mediated increased Net JHCO3 and
endothelin A-receptor-mediated TII through augmented
intrinsic acid production.
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Rats fed standard casein (CAS)-containing laboratory chow
ad libitum have glomerulosclerosis (GS) and tubulo-inters-
titial injury (TII) by age 2 years1,2 that are ameliorated by
reduced dietary protein intake.3,4 High protein diet (HiPro) as
CAS induces endothelin-mediated kidney acidification that
mediates acid excretion in this setting of increased intrinsic
acid production.5–7 Endothelin has been implicated as a
mediator of GS and TII8,9 and so might contribute to GS and
TII associated with HiPro. Consequently, GS and TII observed
with HiPro might be a long-term detrimental consequence of
mechanisms that achieve the short-term benefit of increased
acid excretion in response to increased intake of acid-
producing protein. On the other hand, GS and TII associated
with HiPro might be due to increased dietary protein per se
without regard to effects on net acid production. Male
Munich–Wistar rats are at higher risk for GS and TII with
aging compared with other strains,10 and it was in this strain
that HiPro-induced, endothelin-mediated augmented kidney
acidification was shown.5–7 These studies tested the following
hypotheses: (1) HiPro-induced GS and TII are mediated
through increased intrinsic acid production and (2) enhanced
endothelin action mediates GS and TII in this setting.
RESULTS
Effect of HiPro on body weight
Body weight was higher at 96 weeks in 50 than 20% CAS
(422717 vs 341716 g, Po0.02) but was similar in 50 and
20% SOY (258711 vs 24078 g, P¼ 0.82). By contrast, body
weight was similar among 50% CAS, additionally eating
NaHCO3, NaCl, or Na2SO4 (406716, 412712, and 383717,
respectively, P¼ 0.56) and was also similar among 50% CAS
additionally ingesting no antagonist, bosentan, or darusentan
(419718, 356716, 388714, P¼ 0.06). Likewise, body
weight was similar among 50% SOY eating NaCl, Na2SO4,
or (NH4)2SO4 (266711, 25279, and 23978 g, respectively,
P¼ 0.20) and among 50% SOY additionally ingesting no
antagonist, bosentan, or darusentan (249711, vs 24379,
and 23679 g, respectively, P¼ 0.38).
Effect of HiPro on urine and fecal nitrogen excretion
Although daily food intake was similar between 50 and 20%
CAS and SOY, 50% compared with 20% animals had higher
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urine nitrogen excretion whether with CAS (556759 vs 2717
29 mg/day, Po0.005) or SOY (445747 vs 226725 mg/day,
Po0.007). Similarly, fecal nitrogen excretion was higher in
50% compared with 20% animals whether with CAS (4076
vs 1873 mg/day, Po0.017) or SOY (2373 vs 1173 mg/day,
Po0.03).
Effect of HiPro on plasma TCO2 of conscious rats
Plasma TCO2 was lower in 50 than 20% CAS at 12 weeks
(23.070.6 vs 25.270.6 mM, Po0.04) and 96 weeks
(22.670.7 vs 24.970.5 mM, Po0.04), but was similar in 50
and 20% SOY at both 12 weeks (27.370.6 vs 26.670.7 mM,
P¼ 0.78) and 96 weeks (27.070.6 vs 26.370.6 mM,
P¼ 0.42). Plasma TCO2 was similar among NaCl-, Na2SO4-,
and NaHCO3-eating 50% CAS at 12 weeks (23.970.7,
24.270.7, and 25.470.8 mM, P¼ 0.18) and 96 weeks
(23.170.5, 23.370.6, and 24.670.6 mM, respectively,
P¼ 0.23). Plasma TCO2 was also similar among 50% CAS
ingesting no antagonists and those ingesting bosentan or
darusentan at 12 weeks (23.270.5, 21.870.6, 23.070.6 mM,
respectively, P¼ 0.28) or 96 weeks (23.070.6, 22.070.5,
23.170.6 mM, respectively, P¼ 0.31). Likewise, plasma TCO2
was similar among NaCl-, Na2SO4-, and (NH4)2SO4-eating
50% SOY at 12 (26.170.6, 26.370.6, and 25.870.7 mM,
P¼ 0.59) and 96 weeks (26.470.6, 26.270.6, and
25.670.6 mM, P¼ 0.56) and among 50% SOY ingesting no
antagonists and those ingesting bosentan or darusentan at 12
(P¼ 0.38) or 96 weeks (P¼ 0.47).
Effect of HiPro on urine net acid excretion of conscious rats
Urine net acid excretion (NAE) was higher in 50 than 20%
CAS at 12 weeks (825471047 vs 42937476 mm/day,
Po0.004) and 96 weeks (869171104 vs 44807513 mm/day,
Po0.004) but was not different between 50 and 20% SOY at
12 weeks (16987247 vs 18037332 mm/day, P¼ 0.80) or 96
weeks (13097211 vs 15427255 mm/day, P¼ 0.49). Higher
urine NAE in 50 than 20% CAS was due to higher
ammonium (NH4
þ ) excretion and lower HCO3 excretion
but titratable acidity (TA) excretion was similar as shown
previously.5,7 Urine NAE was lower in 50% CAS eating
NaHCO3 (36587470 and 35697387 mm/day at 12 and 96
weeks, respectively) than 50% CAS eating either NaCl
(77547816 and 78727984 mm/day, Po0.002 vs NaHCO3)
or Na2SO4 (79637902 and 81977996 mm/day, Po0.003 vs
NaHCO3). Lower NAE in NaHCO3 animals was predomi-
nantly due to lower NH4
þ excretion compared with the
NaCl- and Na2SO4 eating 50% CAS (19397207 vs
46247527 and 50997628 mm/day, respectively, Po0.001).
Urine HCO3 excretion at 12 weeks was similar in NaHCO3-
and NaCl-eating 50% CAS (270753 and 227732 mm/day,
respectively, P¼ 0.50), but this parameter in these groups was
higher than the Na2SO4-eating 50% CAS (101715 mm/day,
Po0.03). By contrast, titratable acidity excretion was similar
among NaHCO3-, NaCl-, and Na2SO4 eating CAS
(19397251, 33577410, and 29667373 mm/day, respectively,
P¼ 0.06). These comparisons were qualitatively identical at
96 weeks of age. Urine NAE was not different among 50%
CAS ingesting and not ingesting bosentan or darusentan. In
addition, urine NAE was higher in 50% SOY eating
(NH4)2SO4 (34157414 mm/day) than eating NaCl or Na2SO4
(15127186 and 17047192 mm/day, respectively, Po0.01,
each vs (NH4)2SO4) at 12 weeks; the comparisons were
qualitatively similar at 96 weeks. The higher UAE in 50%
SOYþ (NH4)2SO4 compared with 50% SOYþNaCl and
50% SOYþNa2SO4 was due to higher NH4þ excretion
(23557260 vs 9107102 and 11227120 mm/day, Po0.01)
and lower HCO3 excretion (51710 vs 286731 and
186719 mm/day, Po0.01). Urine NAE was not different
among 50% SOYþ (NH4)2SO4 ingesting and not ingesting
bosentan or darusentan.
Effect of HiPro on GFR
Glomerular filtration rate (GFR) was higher in 50 than 20%
CAS at 12 weeks (23677221 vs 15507139 ml/min, Po0.007)
and 96 weeks (21817208 vs 14767126 ml/min, Po0.012).
Similarly, GFR was higher in 50 than 20% SOY at 12 weeks
(16547143 vs 11067102 ml/min, Po0.008) and 96 weeks
(16137140 vs 11277109 ml/min, Po0.016). The respective
12- and 96-week GFRs were not different within CAS or SOY.
GFR was similar among 50% CAS eating NaCl, Na2SO4, or
NaHCO3 at 12 weeks (25877228, 24907219, and
25107232 ml/min, respectively, P¼ 0.86) and 96 weeks
(22177205, 21307211, and 25667241 ml/min, respectively,
P¼ 0.58). GFR was not different among 50% CAS ingesting
neither antagonist, bosentan, or darusentan at 12 weeks
(23437222, 24127213, and 26547240 ml/min, respectively,
P¼ 0.71) or 96 weeks (22897232, 23937227, and
24437236 ml/min, respectively, P¼ 0.74). GFR was similar
among 50% SOY eating NaCl, Na2SO4, or (NH4)2SO4 at 12
weeks (17327156, 16717144, and 16027139 ml/min, re-
spectively, P¼ 0.67) and 96 weeks (17717161, 16217154,
and 14617135 ml/min, respectively, P¼ 0.49). GFR was not
different among 50% SOY ingesting neither antagonist,
bosentan, or darusentan at 12 weeks (16537162,
15987148, and 16447151 ml/min, respectively, P¼ 0.96)
and 96 weeks (15747143, 15897146, and 16257132 ml/
min, respectively, P¼ 0.81).
Effect of HiPro on distal nephron acidification
Net HCO3 reabsorption (Net JHCO3) by in vivo microperfu-
sion was carried out at 12 weeks only. Net JHCO3 was higher
in 50 than 20% CAS (25.072.3 vs 13.871.5 pmol/mm.min,
Po0.001) as shown previously5–7 but Net JHCO3 was similar
in 50 and 20% SOY (6.771.3 vs 9.071.9 pmol/mm.min,
P¼ 0.34). Figure 1a (upper graph) shows lower Net JHCO3 in
50% CAS eating NaHCO3 than the remaining salts. Figure 1a
(lower graph) also shows lower Net JHCO3 in 50% CAS
ingesting bosentan but not darusentan. The upper graph of
panel b shows higher Net JHCO3 in 50% SOY eating
(NH4)2SO4 than the remaining salts. The lower graph of
panel b shows lower Net JHCO3 in 50% SOY ingesting
bosentan but not in 50% SOY ingesting darusentan.
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Effect of HiPro on urine ET-1 excretion (UET-1V) of
conscious rats
Figure 2 shows UET-1V at 12 weeks only because comparisons
were qualitatively identical for each parameter within groups
at 12 weeks and 96 weeks. The upper graph shows higher
UET-1V in 50 than 20% CAS (76.977.7 vs 35.374.0 fmole/kg
bw/day, Po0.02) but shows similar UET-1V in 50 and 20%
SOY (49.476.2 vs 42.874.0 fmole/kg bw/day, P¼ 0.39). The
middle graph shows lower UET-1V in 50% CAS eating
NaHCO3 (32.173.5 fmole/kg bw/day) than 50% CAS eating
NaCl or Na2SO4 (52.876.2 and 50.875.5 fmole/kg bw/day,
respectively, Po0.04, each vs NaHCO3 group). The lower
graph of Figure 2 shows higher UET-1V in 50% SOY eating
(NH4)2SO4 (53.673.6 fmole/kg bw/day) than NaCl or
Na2SO4 (35.972.7 and 40.972.9 fmole/kg bw/day, respec-
tively, Po0.05, each vs (NH4)2SO4).
Effect of HiPro on urine excretion of indicators of kidney
injury
Figure 3 (upper graph) shows that urine albumin excretion
(UalbuminV) was higher in 50 than 20% CAS at 96 weeks
(Po0.05). By contrast, UalbuminV was not different between
50 and 20% SOY up to 96 weeks. The middle graph shows
lower UalbuminV in 50% CAS eating NaHCO3 than either
NaCl or Na2SO4 at 96 weeks (Po0.05). The lower graph of
Figure 3 shows higher UalbuminV in 50% SOY eating
(NH4)2SO4 than eating NaCl or Na2SO4 at 96 weeks
(Po0.05). Figure 4 (upper graph) shows that urine excretion
of transforming growth factor b (UTGFV) was higher in 50
than 20% CAS at 96 weeks (Po0.03). By contrast, UTGFV
was not different between 50 and 20% SOY up to 96 weeks.
The middle graph shows lower UTGFV in 50% CAS eating
NaHCO3 than eating NaCl or Na2SO4 at 96 weeks (Po0.05).
The lower graph shows higher UTGFV in 50% SOY eating
(NH4)2SO4 than eating NaCl or Na2SO4 at 96 weeks
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Figure 1 | Distal nephron acidification at age 12 weeks as measured by net HCO3 reabsorption (Net JHCO3) by in vivo microperfusion.
(a) Upper graph shows animals eating 50% CAS with the indicated salt; *Po0.05 vs NaCl. Lower graph shows animals eating 50% CAS
without antagonist, with endothelin A/B receptor antagonist bosentan, or with endothelin A receptor antagonist darusentan; *Po0.05 vs
group without either antagonist. (b) Upper graph shows animals eating 50% SOY with the indicated salt; *Po0.05 vs NaCl. Lower graph
shows animals eating 50% SOY without antagonist, with endothelin A/B receptor antagonist bosentan, or with endothelin A receptor
antagonist darusentan; *Po0.05 vs group without either antagonist.
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Figure 2 | Urine endothelin-1 (ET-1) excretion (UET-1V) at age
12 weeks in conscious animals. (a) Left part compares 50 vs 20%
CAS; right part compares 50 vs 20% SOY; *Po0.05 vs respective 20%
diet. (b) 50% CAS with the indicated salt; *Po0.05 vs NaCl. (c) SOY
(50%) with the indicated salt; *Po0.05 vs NaCl.
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(Po0.05). Figure 5 (upper graph) shows that urine excretion
of N-acetyl-b-D-glucosaminidase (UNAGaseV) was higher in
50 than 20% CAS at 96 weeks (Po0.02). By contrast,
UNAGaseV was not different between 50 and 20% SOY up to
96 weeks. The middle graph shows lower UNAGaseV in 50%
CAS eating NaHCO3 than eating NaCl or Na2SO4 at 96 weeks
(Po0.03). The lower graph of Figure 3 shows higher
UNAGaseV in 50% SOY eating (NH4)2SO4 than eating NaCl
or Na2SO4 at 96 weeks (Po0.04).
Effect of ET-1 receptor antagonists on HiPro-induced changes
in excretion of kidney injury indicators
The upper graph of Figure 6 shows that darusentan, but not
bosentan, reduces UalbuminV in 50% CAS (Po0.04), and the
lower one shows that darusentan, but not bosentan, reduces
UalbuminV in 50% SOY eating (NH4)2SO4 (Po0.05).
Similarly, the upper graph of Figure 7 shows that darusentan
but not bosentan reduces UTGFV in 50% CAS (Po0.05), and
the lower one shows that darusentan, but not bosentan,
reduces UTGFV in 50% SOY eating (NH4)2SO4 (Po0.05).
Finally, the upper graph of Figure 8 shows that darusentan,
but not bosentan, reduces UNAGaseV in 50% CAS (Po0.03),
and the lower one shows that darusentan, but not
bosentan, reduces UNAGaseV in 50% SOY eating (NH4)2SO4
(Po0.05).
HiPro effect on kidney pathology
Figure 9 shows no difference in GS index between 50 and
20% CAS, among 50% CAS eating the three Naþ salts, or
among 50% SOY eating NaCl, Na2SO4, or (NH4)2SO4. By
contrast, the upper graph of the TII index panel shows that
TII was higher in 50 than 20% CAS (2.2570.21 vs
1.2570.13 U, Po0.03) but not between 50 and 20% SOY
(0.5070.06 vs 0.5570.07 U, P¼ 0.71). The middle graph
shows that TII was lower in 50% CAS eating NaHCO3
(1.3070.11 U) than eating NaCl or Na2SO4 (2.1170.20 and
2.2070.22 U, respectively, Po0.05 each vs NaHCO3). The
lower graph shows greater TII in 50% SOY eating (NH4)2SO4
(0.870.09 U) than NaCl or Na2SO4 (0.0570.0.07 and
0.770.0.08 U, respectively, Po0.05 each vs (NH4)2SO4).
Effect of ET-1 receptor antagonists on HiPro-induced changes
in kidney pathology
Figure 10 shows no GS index differences among 50% CAS or
50% SOYþ (NH4)2SO4 ingesting or not ingesting bosentan
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Figure 3 | Urine albumin excretion (UalbuminV). (a) 50 vs 20% CAS
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Figure 4 | Urine transforming growth factor b excretion
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or darusentan. By contrast, Figure 10 shows lower TII in 50%
CAS ingesting darusentan (1.4270.13 vs 2.2970.22,
Po0.05), but not bosentan (2.2270.18). Similarly, TII was
lower in 50% SOYþ (NH4)2SO4 ingesting darusentan
(0.5570.06 vs 0.8770.09, Po0.05), but not bosentan
(0.8070.09).
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DISCUSSION
These studies tested the hypothesis that HiPro-associated
kidney injury in Munich–Wistar rats is mediated by
augmented intrinsic acid production through endothelin
receptors. The data show that HiPro with acid-producing
CAS but not non-acid-producing SOY induced greater (1)
distal nephron acidification; (2) urine excretion of kidney
injury parameters, and (3) TII. Reduced intrinsic acid
production with concomitant NaHCO3, but not NaCl or
Na2SO4, ameliorated each of the above parameters. Con-
versely, dietary acid ((NH4)2SO4) with HiPro SOY induces
greater (1) distal nephron acidification, (2) urine excretion of
kidney injury parameters, and (3) TII. These data support
that increased intrinsic acid production induces kidney
injury in this setting. Endothelin A/B but not A-receptor
antagonism reduced augmented distal nephron acidification
induced by either HiPro CAS or concomitant dietary acid
with HiPro SOY. By contrast, endothelin A, but not A/B
receptor antagonism, ameliorated HiPro CAS-induced and
dietary acid-induced urine indices of kidney injury and TII.
No examined intervention ameliorated GS. The data support
that increased intrinsic acid production by HiPro CAS induces
endothelin B receptor-mediated augmented distal nephron
acidification and endothelin A-receptor-mediated TII.
Most studies of HiPro-induced kidney injury used rats
with reduced nephron mass, a setting that enhances HiPro
effects on kidney injury.11 GS and TII induced by HiPro CAS
in the animals of the present studies with intact nephron
mass was comparatively less than in animals with reduced
mass12 and were not associated with decreased GFR as in rats
with reduced mass.11 HiPro CAS might induce less injury in
rat strains that are less associated with GS and TII than the
susceptible Munich–Wistar strain chosen for these studies. In
any case, increased intrinsic acid production induced by
HiPro CAS appears to be a contributing factor to kidney
injury that occurs in genetically susceptible animals with
intact nephron mass and/or in less genetically susceptible
animals with reduced nephron mass.
HiPro CAS increases kidney endothelin production as
measured by increased urine endothelin excretion,5–7 in-
creases kidney cortical parenchymal endothelin as deter-
mined by microdialysis in vivo,7 and increases kidney cortical
mRNA.7 HiPro with non-Hþ -producing SOY was not
associated with increased urine endothelin excretion, a
surrogate of increased kidney endothelin production,7 but
concomitant dietary acid with HiPro SOY increased urine
endothelin excretion. Furthermore, HiPro CAS with con-
comitant NaHCO3 had lower urine endothelin excretion.
Together, these data support that HiPro CAS increases kidney
endothelin production through increased intrinsic acid
production.
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Figure 9 | Indices of GS (left column) and TII (right column).
(a) GS (left graph) and TII (right graph) in 50 vs 20% CAS or 50 vs
20% SOY; *Po0.05 vs respective 20% diet. (b) GS (left graph) and
TII (right graph) in 50% CAS with indicated salts; *Po0.05 vs NaCl.
(c) GS (left graph) and TII (right graph) in 50% SOY with indicated
salts; *Po0.05 vs NaCl.
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Figure 10 | Effect of endothelin receptor A/B antagonism with
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on indices of GS (left column) and TII (right column). (a) GS
(left graph) and TII (right graph) in 50% CAS; *Po0.05 vs respective
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50% SOY with indicated salts; *Po0.05 vs respective group without
either drug.
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Augmented tubule acidification induced by chronic diet-
ary intake of mineral acid is mediated through endothelin B
receptors in both the proximal13 and distal14 nephron. These
studies support that endothelin B receptors mediate the
physiologically beneficial effect of augmented distal nephron
acidification induced by HiPro CAS. On the other hand, the
data support that endothelin A receptors mediate kidney
injury associated with HiPro CAS. Kidney injury in other rat
models is also mediated through endothelin A receptors.6,15
These data suggest that endothelin A antagonists might
ameliorate kidney injury induced by HiPro without com-
promising the physiologically beneficial effect of increased
kidney acidification in response to the associated acid
challenge to systemic acid-base status.
These reported studies support that increased intrinsic
acid production associated with HiPro CAS induces TII but
is less associated with GS. Chronic TII in some rat models has
been associated with increased NH4
þ production induced by
a chronic dietary acid load.16 The present and previous
studies5,7 showed greater urine NH4
þ excretion in HiPro CAS
animals and in the HiPro SOY animals concomitantly
ingesting dietary acid. Furthermore, HiPro CAS animals
eating NaHCO3 had less urine NH4
þ excretion and less TII.
The present studies are consistent with these earlier ones16
supporting that HiPro CAS-induced kidney NH4
þ produc-
tion contributed to TII in these animals.
In summary, HiPro as Hþ -producing CAS but not as
non-Hþ -producing SOY increases kidney endothelin pro-
duction, augments distal nephron acidification, and induces
TII. The data support that endothelin B receptors mediate
the increased distal nephron acidification and that endothelin
A receptors mediate TII. The data suggest that as yet
undetermined consequences of increased intrinsic acid
production contribute to TII through endothelin A receptors.
MATERIALS AND METHODS
Animals and diet protocol
The protocol for these animal studies was approved by our Local
Institutional Review Board. Male Munich–Wistar rats (Harlan
Sprague-Dawley, Houston, TX, about 8 weeks old) ate standard
rat chow (Prolab RMH 2500 with 23% protein of various sources,
Purina Labs, St Louis, MO, USA) for at least 1 week before being
changed to a minimum electrolyte diet (MED) with protein as
purified high nitrogen CAS or as SOY without isoflavones (ICN
Nutritional Biochemicals, Cleveland, OH, USA), while drinking
distilled H2O. The first aim was to compare effects of diets with acid
producing and non-acid-producing dietary protein. Metabolism of
dietary CAS protein yields net acid but metabolism of dietary SOY
protein does not17 and so MED with protein provided as CAS or
SOY was used for this comparison. Because CAS induces greater
protein synthesis and degradation than the equivalent intake of
SOY,18 HiPro was compared within CAS or SOY groups but not
between CAS and SOY. Animals ate MED with 50% (HiPro) or 20%
protein and were fed the same daily amount to assure comparable
intakes and complete intake of antagonists mixed with diet. All 50%
CAS Munich–Wistar rats survived to 96 weeks and had higher
indices of GS and TII (see below) than 20% Munich–Wistar, 50%
Sprague Dawley, and 20% Sprague Dawley similarly followed.
The second aim was to relate the hypothesized effects of HiPro
CAS diet to increased intrinsic acid production. MED with 50% but
not 20% CAS induces endothelin-dependent augmented distal
nephron acidification.7–9 We studied additional animals eating 50%
CAS with Naþ salts that do and do not reduce net acid production
and urine NAE. Dietary NaHCO3 was used to reduce urine NAE,
consistent with decreased net Hþ production.19,20 Two Naþ
ingesting controls provided similar Naþ intake with non-HCO3
salts to rule out independent effects of added Naþ in these animals
eating MED. Dietary NaCl but not Na2SO4 induces distal nephron
HCO3 secretion
14 so Na2SO4 was an additional control. The Na
þ /
Cl content of standard diet was 174/200 mM/g, respectively, and that
for MED was 22/14mM/g, respectively. To avoid a Naþ load that was
much greater than the standard diet, 150mM/g of NaHCO3 and
NaCl, or 75 mM/g Na2SO4 was added to MED to comprise the three
groups. To further test the hypothesis that the effects of HiPro CAS
was due to increased intrinsic acid production, we studied animals
eating 50% SOY that also ingested dietary acid. We added
(NH4)2SO4 (75mM/g) as dietary acid, because it does not induced
distal nephron HCO3 secretion as does NH4Cl.
14
The third study aim was to determine if HiPro CAS effects were
mediated through endothelin A and/or B receptors. Some HiPro
CAS animals received bosentan (Actelion, Allschwil, Switzerland), a
nonpeptide endothelin A/B receptor antagonist,21 mixed with diet at
100 mg/kg bw/day.5–7 Others received the endothelin A receptor
antagonist darusentan (Knoll, AG, Ludwigshafen/Rhein, Ger-
many)22 mixed with diet at 20 mg/kg bw/day. This oral dose of
darusentan reduces GS and proteinuria in a puromycin model of
kidney injury in aging rats.23 Each antagonist-receiving group was
compared to those without antagonist.
In the first study phase, four 8-week-old animals in each
experimental group received standard diet for 1 week and were then
changed to one of the custom diets without or with one of the
receptor antagonists for the remainder of the protocol. Twenty-four
hour urine collections at 12-week intervals for 96 weeks measured
excretion of albumin, TGFb-1, and N-acetyl-b-D-glucosaminidase
(NAGase) as surrogates of kidney injury. Urine albumin excretion
was used to assess general kidney injury,24 TGFb as a surrogate that
is possibly more specific for injury related to increased intracellular
matrix production,25 and NAGase as a surrogate26 that is possibly
more specific for TII.27 At age 96 weeks, GFR was measured in
anesthetized animals.28 Animals were killed and their left kidneys
subjected to light microscopic examination by a kidney pathologist
blinded as to the group and were scored according to degree of GS
and TII.29 Briefly, GS severity was determined on a 0–4þ scale as
follows: 0, normal glomeruli; 1þ , o25% of the glomerulus was
sclerotic; 2þ , o50% was sclerotic; 2þ , o75% was sclerotic; 3þ ,
o75% was sclerotic; and 4þ , 75–100% was sclerotic. The degree of
TII was also determine on a 0–4þ scale: 0, normal tubules/
interstitium; 1þ , area involved o25% of tubules and interstitium
showing tubular atrophy, interstitial inflammation, and/or atrophy;
2þ , tubulointerstitial changes involving o50% of observed fields;
3þ , involving o75% of observed fields; and 2þ , involving
75–100% of observed fields.
In the second phase, eight 8-week-old animals received standard
diet for 1 week and were changed to a custom diet without or with
one of the receptor antagonists for 3 weeks. Twenty-four hour urine
NAE was measured in conscious animals30 on protocol day 28 in
eight animals of each experimental group. Animals then underwent
vivo microperfusion micropuncture of accessible distal nephrons.31
In situ early distal flow rate for 50 vs 20% CAS animals was 9.470.7
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(n¼ 6) vs 6.470.4 nl/min (n¼ 8). In situ early distal flow rate for 50
SOY vs 20% SOY was 5.370.5 (n¼ 6) vs 5.870.5 nl/min (n¼ 8).
Because there are no qualitative differences in Net JHCO3 in 50%
compared to 20% CAS eating rats whose distal nephrons are
perfused at either 6 or 9 nl/min,5 distal nephrons of all animals were
perfused at 6 nl/min with a Hampel pump.31
Determination of urine and fecal nitrogen excretion
Four of each of 50 and 20% CAS and SOY animals were kept in
individual metabolic cages 4 weeks (1 week standard diet, 3 weeks of
experimental diet) to measure urine and fecal nitrogen excretion at
age 12 weeks to assure that protein intake was higher in the
corresponding 50 than 20% animals. Urine (in containers with HCl)
and feces were collected separately during the last 24 h of the
protocol. Feces were freeze dried and stored at 21C, as was urine, for
nitrogen measurement using the semi-micro Kjeldahl method.32
Analytical methods
Initial/collected perfusate and stellate vessel plasma samples were
analyzed for inulin31 and for TCO2 using ultrafluorometry.
33,34
Urine (ET-1) was measured35 as carried out previously.14 Arterial
blood total CO2 (TCO2) was measured by ultrafluormetry (see
below) in four separate, conscious animals from each experimental
group, at ages 12 and 96 weeks.
Data were expressed as means7s.e. In vivo microperfusion data
were analyzed and reported as carried out previously.5 There were
eight animals in each microperfusion and urine NAE group. All
pathology and groups contained four animals except the 50% SOY
groups, which contained eight animals.
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